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Letters to the Editor 
Dear Editor 
Menthol and aspirin-induced asthma 
I read with interest the recent short report by 
Tamaoki et al. on the effect of menthol vapour in 
mild asthmatics (1). However, they did not comment 
on the effect of menthol in aspirin-induced asthma. 
Subiza et al. reported on an aspirin-sensitive patient 
whose asthma was exacerbated by the mint flavour 
contained in her toothpaste (2). They performed the 
challenge test and showed that the mint and menthol 
contained as flavouring in toothpastes may act as 
asthma-inducing agents. 
I have experienced three patients with aspirin- 
induced asthma who also complained of dyspnoea 
when they brushed their teeth, chewed gum with mint 
flavour, or had a cough drop. I pointed out the 
resemblance of chemical structures in aspirin, 
parabens, and artificial flavours (3). Recently I 
encountered two more patients with aspirin-induced 
and mint-flavour-sensitive asthma. In one patient, the 
challenge test with his flavoured toothpaste was 
performed. Immediate response (decrease in FEV, 
from 4.30 1 to 3.81 1) was obtained after he had used 
his toothpaste. A challenge was then performed with 
menthol, one of the components of the patient’s 
toothpaste. The patient was instructed to rinse his 
mouth with 25 mg of menthol diluted in 50 ml of 5% 
alcohol for 1 min and then spit it out. Five minutes 
later, FEV, was decreased from 4.49 1 to 4.08 1. The 
patient complained of tightness. 
Therefore, it seems that menthol vapour does not 
have a beneficial effect on aspirin-induced asthma. 
H. KAWANE 
Kawasaki Medical School 
Kurashiki City 701-01, Japan 
25 August 1995 
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Reply to Dr Kawane 
We thank Dr Kawane for raising the possibility 
that menthol could deteriorate asthmatic symptoms 
in patients with aspirin- and mint-flavour-sensitive 
asthma. Although such patients were not included in 
our study, two patients complained of uncomfortable 
sensation in the upper airway immediately after 
menthol inhalation. These patients were withdrawn 
from our study protocol and, thus, we did not assess 
their airway reactivity. The mechanism of efficacy of 
menthol on airway hyper-responsiveness remains 
unknown, but this cyclic alcohol stimulates laryngeal 
cold receptors (l), inhibits cough reflex (2), stimulates 
airway epithelial Cl secretion through a Ca”- 
dependent mechanism (3,4) and directly relaxes air- 
way smooth muscle (unpubl. data). We speculate that 
these actions could be involved in the observed effect 
of menthol in our study. 
J. TAMAOKI, A. CHIYOTANI 
A. SAKAI, H. TAKEMURAAND 
K. KONNO 
First Department of Medicine 
Tokyo Women’s Medical College 
Tokyo, Japan 
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Dear Editor 
Raised brain natriuretic peptide in pulmonary 
hypertension 
The interesting observations on brain natriuretic 
peptide (BNP) in association with pulmonary 
hypertension as described recently (1) raises the issue 
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of whether the secretion of this group of peptides 
could be beneficial, and whether hypoxia or hyper- 
ventilation plays a role in their release. It prompts me 
to report our findings when we investigated the acute 
effects of these stimuli upon plasma ANP levels, 
previously only published in abstract form (2). 
Six normal volunteers were studied using a 
rebreathing circuit with a spirometer to measure rate 
and minute volume. A soda lime CO, absorber with 
variable bypass controlled inspired carbon dioxide, 
as measured by end-tidal (ET) CO,. Inspired 0, 
content was monitored at the inspiratory limb of the 
circuit. Oxygen saturation (&O-J was measured by 
pulse oximetry. The subjects were allowed 10 min 
run-in period, then rebreathed 6 1 of air for 20 min 
and baseline values obtained. Hypoxia was induced 
by replacing 4 1 of the air with nitrogen to attain a 
SuO, level of 75580% for 20 min, additional 0, being 
added as required. End-tidal CO, was maintained 
at 5-5.5 kPa. After a recovery period of 10 min, 
hypocapnic hyperventilation was voluntarily induced 
and the subject maintained his ET CO, at 3-3.5 kPa 
for 20 min. After a further IO-min recovery period, 
combined hypoxia and hypocapnic hyperventilation 
was studied for 20 min using the same variables. 
The experiment was concluded by a further 10 min 
recovery while still breathing through the apparatus. 
Venous blood for plasma ANP was collected 
throughout at lo-min intervals. Statistical analysis 
was by the Friedman statistic for non-parametric 
data. 
The results are summarized in Fig. 1. Acute nor- 
mocapnic hypoxia caused no significant change in 
plasma ANP. Acute hypocapnic hyperventilation 
caused a fall in ANP after 10 and 20 min, from the 
mean baseline of 8.2 & 2.2 pmol 1 - ’ to 2.1 + 1 .O at 
10 min and 4.2 f 1.7 at 20 min (P<O.O5 comparing 
control with both hypocapnic values). The combined 
stimulus caused an initial fall in ANP to 
4.4 f 2.1 pmol 1 - ’ at 10 min followed by a return 
to control levels at 20 min (8.7 f 2.8 pmol). There 
appeared to be an inverse relationship between the 
rate of ventilation and the level of plasma ANP 
but only during control, recovery and hypocapnic 
hyperventilatory states. 
As noted by Prasad et al. (l), in vitro work has 
suggested that acute, severe hypoxia may cause a rise 
in the secretion of ANP, and chronically hypoxic rats 
appeared to deplete right atria1 ANP and have 
elevated levels of plasma ANP (4,5). Studies in man 
have, however, failed to reveal a clear relationship 
between hypoxia and release of ANP. One study of 
hypoxia in man showed a gradual rise in plasma 
ANP reaching significance at 120 min (6) but the 
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Fig. 1 Effect of hypoxia, hypocapnic hyperventilation 
and both stimuli combined upon plasma ANP levels. R, 
recovery period. Studies were run sequentially. 
same group were unable to reproduce this result in 
dogs. Comparable levels and duration of hypoxia 
were used in a study which showed a small rise in 
ANP (7). 
Our acute study did not show a rise in ANP with 
acute hypoxia. It did, however, suggest that an 
increase in ventilatory rate causes a fall in venous 
ANP acutely, which is only detectable during hypo- 
capnia. It is quite possible that increases in plasma 
ANP are consistent only in chronic hypoxia and are 
related to the development of pulmonary hyperten- 
sion rather than hypoxia alone. The case reports 
described raise the possibility that there may be a 
similar stimulus for BNP secretion, although factors 
acting on the ventricle may be more important. 
The ANP assay was generously supported by the 
British Lung Foundation. 
P. S. THOMAS 
Intensive Care Unit, 
Wollongong Hospital 
Wollongong NS W 2500, Australia 
25 September 1995 
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Dear Editor 
Bronchiectasis and Felty’s syndrome 
Following Takanami et aZ.‘s case report (1) and 
discussion regarding an association between rheuma- 
toid arthritis (RA) and bronchiectasis (BR), we 
would like to report a case of BR in a patient known 
to suffer from Felty’s syndrome, an association not 
previously described. Felty’s syndrome is character- 
ized by a combination of RA, splenomegaly and 
leucopaenia and in this case the patient was also 
suffering from Sjiigren’s syndrome (dry eyes, con- 
firmed by a positive Schirmer’s tear test plus an 
auto-immune disease, e.g. RA). 
A 74-year-old man presented to our chest clinic 
complaining of a persistent cough productive of 
purulent sputum and associated with increasing 
breathlessness over a period of several years. He had 
suffered from seropositive nodular RA and Sjiigren’s 
syndrome for approximately 40 yr and had been 
admitted to hospital on one occasion following an 
episode of bronchopneumonia during which Staphy- 
lococcus aureus was isolated in large numbers from 
sputum samples. No immunosuppressive therapy had 
ever been instituted. Physical examination revealed 
bibasal crackles on auscultation of the chest and 
moderate splenomegaly on abdominal palpation. 
Lung function tests revealed an FEV, of 1.30 (55% 
predicted), FVC 2.43 (79% predicted) and FEV,/ 
FVC ratio of 0.53. Chest radiography showed slight 
bibasal shadowing, (a radiograph in 1989 had been 
reported as normal), but CT scanning of the thorax 
revealed severe BR with loss of volume within the left 
and right lower lobes and right middle lobe. A full 
blood count revealed a pancytopaenia with haemo- 
globin 11.4 g dl - I, white cell count 1.3 x lo9 1 - ’ and 
platelets 99 x lo9 l- I. 
In our patient, as in Takanami et a/.‘~ case, the 
onset of RA almost certainly predated the develop- 
ment of BR. However, the presence of Felty’s 
syndrome would result in a greatly increased suscep- 
tibility to infection (due to neutropaenia), in addition 
to the increased risk in RA discussed by Banji and 
Cooke (2). This association may lend some weight to 
their hypothesis that RA increases the incidence of 
respiratory infection, resulting in the development 
of BR. 
S. J. QUANTRILL* AND KMAHMOUD~ 
*North West Lung Centre 
Wythenshawe Hospital 
Manchester and 
TStepping Hill Hospital 
Stockport, UK. 
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